Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia - a study of the Acute Leukemia Working Party of the EBMT.


Journal

Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422

Informations de publication

Date de publication:
02 2021
Historique:
pubmed: 13 10 2020
medline: 28 4 2021
entrez: 12 10 2020
Statut: ppublish

Résumé

The Acute Leukemia Working Party (ALWP) of the EBMT assessed the outcome of allogeneic stem cell transplantation (alloSCT) in patients with relapsed/refractory AML (r/rAML) evaluating six sequential conditioning regimens (SR) groups. A total of 2132 patients were included. LFS at 2 years was 28.9%, 33.6%, 35.3%, 20.6%, 24.4%, and 27% for the FLAMSA-TBI4, FLAMSA-Chemo, Mel-Flu-TBI8, Mel-Treo-Flu, Thio-ETO-Cy-Bu2-Flu, and Clo-ARAC-(Bu2/TBI4)-Cy groups, respectively. In patients <55 years of age Mel-Flu-TBI8 had the best LFS, which was statistically significant only in comparison to the Mel-Treo-Flu group, while in patients ≥55 years LFS was best with FLAMSA-Chemo without significant differences compared to FLAMSA-TBI4 and Mel-Flu-TBI8. Furthermore, best NRM rates were obtained with the two FLAMSA regimens groups. Our study suggests that in younger (<55 years) patients a more intense regimen might be used whereas in older (≥55 years) patients the focus might be more on tolerability.

Identifiants

pubmed: 33040622
doi: 10.1080/10428194.2020.1827248
doi:

Substances chimiques

Busulfan G1LN9045DK

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

399-409

Auteurs

Thomas Heinicke (T)

Department of Hematology and Oncology, Otto-von-Guericke University, Magdeburg, Germany.

Myriam Labopin (M)

Department of Hematology and Cell Therapy, Hopital Saint-Antoine, Paris, France.
Acute Leukemia Working Party of EBMT Office, Hopital St. Antoine, Paris, France.

Emmanuelle Polge (E)

Acute Leukemia Working Party of EBMT Office, Hopital St. Antoine, Paris, France.

Matthias Stelljes (M)

Department of Internal Medicine A, University of Muenster, Muenster, Germany.

Arnold Ganser (A)

Department of Haematology, Hemostasis, Oncology, Hannover Medical School, Hannover, Germany.

Johanna Tischer (J)

Department of Internal Medicine III, Hematopoietic Stem Cell Transplantation, University Hospital of Munich-Campus Grosshadern, LMU, Munich, Germany.

Arne Brecht (A)

DKD Helios-Klinikum, KMT-Abteilung, Wiesbaden, Germany.

Nicolaus Kröger (N)

Department of Stem Cell Transplantation, University Hospital Eppendorf, Hamburg, Germany.

Dietrich W Beelen (DW)

Department of Bone Marrow Transplantation, University Hospital Essen, Essen, Germany.

Christof Scheid (C)

I Department of Medicine, University of Cologne, Cologne, Germany.

Wolfgang Bethge (W)

Medizinische Klinik II, University Tübingen, Tübingen, Germany.

Peter Dreger (P)

Medizinische Klinik u. Poliklinik V, University of Heidelberg, Heidelberg, Germany.

Donald Bunjes (D)

Klinik fuer Innere Medzin III, University Hospital Ulm, Ulm, Germany.

Eva Wagner (E)

Department of Hematology, Oncology and Pneumology, University Medical Center Mainz, Mainz, Germany.

Uwe Platzbecker (U)

Medical Clinic and Policlinic 1, University Hospital Leipzig, Leipzig, Germany.

Bipin N Savani (BN)

Division of Hematology-Oncology, Vanderbilt University Medical Center, Brentwood, TN, USA.

Arnon Nagler (A)

Acute Leukemia Working Party of EBMT Office, Hopital St. Antoine, Paris, France.
Hematology Division and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer and Tel Aviv University, Tel HaShomer, Israel.

Mohamad Mohty (M)

Department of Hematology and Cell Therapy, Hopital Saint-Antoine, Paris, France.
Acute Leukemia Working Party of EBMT Office, Hopital St. Antoine, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH